Skip to main content

SIGNIFICANT REDUCTION IN BOTH ITCH AND HIVES IN PATIENTS AGED 12+ YEARS

uaS7 - WEEKLY disease activity
(UAS7=ISS7 + HSS7; Week 12 and Week 24, secondary endpoint)1,2

CUPID-A

Mean UAS7 at baseline—DUPIXENT: 32.10 (SD, 7.01); placebo: 30.76 (SD, 8.19).2

CUPID-C
48%

vs 32% reductiona in UAS7 at Week 24
(DUPIXENT: -15.61 vs placebo: -11.27; P=0.0324, secondary endpoint)1,2

  • 36% vs 27% reductiona in UAS7 at Week 12 (DUPIXENT: -12.59 vs placebo: -9.65, secondary endpoint; not significant)2
  • Mean UAS7 at baseline: DUPIXENT (n=73): 28.48 (SD, 7.10); placebo (n=75): 27.86 (SD, 7.82)2

Definitive conclusions cannot be made for Week 12 as the analysis was not multiplicity controlled.

aLSM change from baseline.

IMPROVEMENT IN UAS7 WAS OBSERVED AS EARLY
AS WEEK 3 IN A POST HOC POOLED ANALYSIS

cupid-a and cupid-c pooled analysis2

CUPID-A
CUPID-C

Mean UAS7 at baseline—DUPIXENT: 30.23 (SD, 7.26); placebo: 29.24 (SD, 8.10).2

Definitive conclusions cannot be made as this was a post hoc analysis which was not multiplicity controlled.

CONSISTENT DISEASE ACTIVITY IMPROVEMENT REGARDLESS OF

ANGIOEDEMA IN A POST HOC POOLED ANALYSIS

Definitive conclusions cannot be made as this was a post hoc subgroup analysis which was not multiplicity controlled.

IN POST HOC POOLED ANALYSES OF CUPID-A AND CUPID-C, IMPROVEMENT IN UAS7:

At Week 24 was consistent regardless of patients’ baseline IgE1,2

At Week 24 was generally consistent regardless of baseline BMI2,b

Definitive conclusions cannot be made as these were post hoc analyses which were not multiplicity controlled.

bAcross BMI stratifications: BMI (kg/m2) <25, ≥25 to <30, and ≥30.

BMI, body mass index; CSU, chronic spontaneous urticaria; HSS7, hives severity score over 7 days; ISS7, itch severity score over 7 days; LSM, least squares mean; SD, standard deviation; UAS7, urticaria activity score over 7 days.

See data for itch and hives separately
EXPLORE ISS7 DATA EXPLORE HSS7 DATA

Use of DUPIXENT for CSU indication in patients aged 2-11 years is supported by evidence from two studies of DUPIXENT in CSU patients 12+ years of age.1

 

Urticaria activity score (UAS) is a patient-reported assessment of urticaria severity. UAS7 is the sum of the preceding 7 days’ itch severity score (ISS) and hives severity score (HSS), for a total UAS7 range of 0 to 42.2

ISS7

0
1-7
8-14
15-21

+

HSS7

0
1-7
8-14
15-21

=

UAS7

0 Urticaria-free
1-6 Well controlled
7-15 Mild
16-27 Moderate
28-42 Severe

SEE WHICH PATIENTS WITH CSU MAY BE APPROPRIATE FOR DUPIXENT

IDENTIFY PATIENTS